Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperglycemia, Diabetes, and Obesity
Interventions: Resistant starch; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 29 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Stroke
Interventions: NA-1, Placebo; Drug
Lead sponsor: NoNO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Phoenix, Arizona • Stanford, California • Portland, Oregon

Conditions: Type 1 Diabetes Mellitus
Interventions: Omnipod Insulin Management System; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Year to 8 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy Volunteer Study
Interventions: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cypress, California

Conditions: Type 2 Diabetes Mellitus
Interventions: 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type2 Diabetes
Interventions: Low Carbohydrate Diet, Time Restricted Feeding; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Madison, Wisconsin

Conditions: Diabetes Mellitus, Type 1
Interventions: Fiasp, Novolog; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Cataract
Interventions: Printed Instructions with Phone Reminders, Sharp Health Companion App (CareKit); Behavioral
Lead sponsor: Sharp HealthCare; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions: Metformin, Insulin; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 26
States / cities: Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more

Conditions: Chronic Hepatitis C
Interventions: telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions: CYT387; Drug
Lead sponsor: Sierra Oncology LLC - a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • Rochester, Minnesota

Conditions: Healthy Volunteer
Interventions: Pirfenidone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Merritt Island, Florida

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Human Immunodeficiency Virus, Metabolic Syndrome
Interventions: Intermittent fasting, Standard of Care; Behavioral · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fasting
Interventions: Dinner, Fasting, Study food; Other
Lead sponsor: L-Nutra Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes, Hyperglycemia
Interventions: insulin glargine; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 30 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Prader Willi Syndrome, Hypoglycemia
Interventions: Infants with Prader-Willi Syndrome; Other
Lead sponsor: University of Florida; Other
Eligibility: 2 Months to 12 Months
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy
Interventions: Levetiracetam, Keppra®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: G-Pen Mini™ (glucagon injection), Glucose Tablets; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more

Conditions: Metabolic Regulation, Fasting, Ketogenic Diet
Interventions: Dietary manipulation ketogenic diet, Dietary Manipulation - 12 day ketogenic diet, 16 Hour Fast; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Long Covid19, Long COVID
Interventions: Low sugar diet and 10-12 hour eating window, Low sugar diet, 8 hour eating window and fasting; Other
Lead sponsor: Pacific Northwest University of Health Sciences; Other
Eligibility: 19 Years to 69 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Boulder, Colorado • Yakima, Washington

Conditions: Type 2 Diabetes
Interventions: Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 118
States / cities: Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more

Search by objective public record fields.

Normal Human Electro-Oculogram

Effects of Resistant Starch in a Baked Snack Bar on a Post-prandial Glycemic and Insulinemic Response

Evaluating Neuroprotection in Aneurysm Coiling Therapy

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Low-Carb/Time-restricted Feeding Protocol in Insulin-Using Type 2 Diabetics

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

Sharp Health Companion App for Cataract Surgery Preparation and Recovery

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

2-5 Intermittent Caloric Restriction in HIV

Effects of Fast Bar on Physiological Fasting

Insulin Secretion in Diabetes Before and After Glycemic Control

Hypoglycemia in Prader-Willi Syndrome

Levetiracetam 1000 mg Under Fasting Conditions

Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia

Effects of Dietary Manipulation on Metabolism in Healthy Adults

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM